As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
9 Analysts have issued a Marker Therapeutics, Inc. forecast:
9 Analysts have issued a Marker Therapeutics, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 5.39 5.39 |
45%
45%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
|
| EBIT (Operating Income) EBIT | -15 -15 |
33%
33%
|
|
| Net Profit | -15 -15 |
41%
41%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
| Head office | United States |
| CEO | Juan Vera |
| Employees | 5 |
| Founded | 1991 |
| Website | markertherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


